FactEvidence 1
partners with艾力斯
No public evidence summary is available.
钛媒体 · 2026-10-08 20:51
View evidence
- Media钛媒体2026-10-08 20:51View source
Company
ArriVent BioPharma
Structure of ArriVent BioPharma
ArriVent BioPharma
Company
1 connections
PeersCompetition and partners
Relationship began
ArriVent BioPharmaCompany · 1 connections
Layer 1PeersCompetition and partners1
Relations
Arrows show the direction of the relationship. Filter to focus on a business area.
- 艾力斯partners with →ArriVent BioPharmaCompany · 艾力斯Evidence 2Fact55%
View evidence
- Media钛媒体2026-10-08 20:51View source
- Media钛媒体2026-10-08 11:17View source
- Company · 艾力斯Evidence 2Fact55%
View evidence
- Media钛媒体2026-10-08 20:51View source
- Media钛媒体2026-10-08 11:17View source
Showing 1 to 2 of 2
Claims
Read the assertion alongside its sources. Expand a row to inspect the evidence.
FactEvidence 1
partners with艾力斯
No public evidence summary is available.
钛媒体 · 2026-10-08 11:17
View evidence
- Media钛媒体2026-10-08 11:17View source
FactEvidence 1
Claims近47%下跌
No public evidence summary is available.
钛媒体 · 2026-10-08 11:17
View evidence
- Media钛媒体2026-10-08 11:17View source
FactEvidence 1
share price changenearly 47 per cent
No public evidence summary is available.
South China Morning Post world · 2026-10-07 12:20
View evidence
- MediaSouth China Morning Post world2026-10-07 12:20View source
Showing 1 to 4 of 4
Market and valuation
Valuation data is available on Pro and Research.
Included in ProNot available: Company signals · Financials · Filings · Guidance